Aratana Therapeutics (PETX) Rating Increased to Buy at BidaskClub

BidaskClub upgraded shares of Aratana Therapeutics (NASDAQ:PETX) from a hold rating to a buy rating in a research report report published on Thursday morning.

PETX has been the topic of several other reports. Stifel Nicolaus upgraded shares of Aratana Therapeutics from a hold rating to a buy rating and raised their target price for the stock from $6.00 to $8.00 in a report on Tuesday, March 27th. CL King upgraded shares of Aratana Therapeutics from a neutral rating to a buy rating and set a $8.00 target price on the stock in a report on Monday, March 12th. They noted that the move was a valuation call. HC Wainwright set a $10.00 target price on shares of Aratana Therapeutics and gave the stock a buy rating in a report on Monday, May 7th. Zacks Investment Research upgraded shares of Aratana Therapeutics from a sell rating to a hold rating in a report on Wednesday, March 7th. Finally, Credit Suisse Group reaffirmed an outperform rating and set a $8.00 price target (down from $9.00) on shares of Aratana Therapeutics in a research note on Friday, March 16th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $8.68.

PETX stock traded up $0.04 during mid-day trading on Thursday, hitting $5.40. 139,259 shares of the company were exchanged, compared to its average volume of 474,133. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.02 and a current ratio of 3.37. The company has a market capitalization of $249.68 million, a P/E ratio of -5.57 and a beta of 2.88. Aratana Therapeutics has a 1-year low of $3.67 and a 1-year high of $7.67.

Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Tuesday, March 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. The firm had revenue of $10.46 million for the quarter, compared to the consensus estimate of $5.72 million. Aratana Therapeutics had a negative net margin of 168.26% and a negative return on equity of 38.97%. analysts forecast that Aratana Therapeutics will post -0.58 earnings per share for the current year.

In other news, insider Peter Steven St sold 11,513 shares of the firm’s stock in a transaction that occurred on Monday, April 30th. The shares were sold at an average price of $5.00, for a total transaction of $57,565.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 5.20% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Franklin Resources Inc. grew its stake in shares of Aratana Therapeutics by 0.5% during the 1st quarter. Franklin Resources Inc. now owns 5,969,371 shares of the biopharmaceutical company’s stock worth $26,325,000 after acquiring an additional 28,969 shares in the last quarter. General American Investors Co. Inc. grew its stake in shares of Aratana Therapeutics by 44.7% during the 1st quarter. General American Investors Co. Inc. now owns 1,617,923 shares of the biopharmaceutical company’s stock worth $7,135,000 after acquiring an additional 500,000 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Aratana Therapeutics by 1.0% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 1,010,448 shares of the biopharmaceutical company’s stock worth $4,456,000 after acquiring an additional 10,404 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Aratana Therapeutics by 30.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 785,096 shares of the biopharmaceutical company’s stock worth $3,462,000 after acquiring an additional 183,294 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Aratana Therapeutics by 38.5% in the first quarter. Wells Fargo & Company MN now owns 639,436 shares of the biopharmaceutical company’s stock valued at $2,820,000 after buying an additional 177,824 shares in the last quarter. 67.71% of the stock is owned by institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply